You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥師幫(09885.HK)獲納入MSCI全球小型股指數

近日,MSCI系列指數公佈了8月份指數審議結果。在本次調整中,MSCI中國指數新納入地平線機器人、老鋪黃金、三生製藥等14只股票;藥師幫、邁富時等19只港股獲納入MSCI中國小盤股指數,相關調整將於8月26日收盤後正式生效。

MSCI中國小盤股指數是由摩根士丹利資本國際公司(MSCI)編制的跟蹤中國小盤股票表現的國際化指數,隸屬於MSCI全球小型股指數(MSCI Global Small Cap Indexes)。該指數爲投資者提供追蹤中國高成長性中小企業的投資工具,這些公司通常具有較高的增長潛力,但市值和流動性相對較低,與MSCI中國指數形成互補。

據悉,MSCI中國小盤股指數成分股篩選嚴格,調整頻繁,緊跟市場動態,是衆多國際投資機構的投資參考依據。指數基金和被動型基金通常會根據指數成分股進行投資,因此納入指數有望帶來更多的被動資金流入。5月份調整中獲納入的生物製藥企業復宏漢霖,自生效日後的累計漲幅超60%。

藥師幫獲納入MSCI中國小盤股指數,是資本市場對公司經營業績及發展潛力的認可,將有助於公司拓寬投資者基礎,進一步增進個股流動性,提升資本市場影響力。藥師幫近期發佈的公告顯示,公司今年上半年淨利潤預期將不少於人民幣7000萬元,爲上年同期3.2倍以上。在醫藥流通市場普遍承壓的背景下,藥師幫憑藉“平臺+自營+自有品牌”驅動模式以及獨特的現金週轉能力逆勢增長。

現階段,藥師幫已覆蓋全國98.9%的縣域和91.2%的鄉鎮,擁有49.1萬藥店用戶及33萬基層醫療機構用戶,規模效應顯著。據統計,中國院外醫藥數字化流通市場規模將在2027年達到3583億元。隨着藥師幫發力自有品牌業務、優化供應鏈提升及基層醫療佈局推進,公司細分領域龍頭優勢將不斷擴大,進入盈利釋放階段,價值潛力巨大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account